GSK

Peers: SNY PFE AZN MRK NVS BMY JNJ ABBV NVO LLY

| Held by: AVDE FENI PPH FVD GMOI RODM DFAX AVIV BINV TOUS

Index	-
Market Cap	101.35B
Enterprise Value	120.81B
Income	6.48B
Sales	44.55B
Book/sh	11.58
Cash/sh	2.06
Dividend Est.	1.85 (3.65%)
Dividend TTM	1.82 (3.59%)
Dividend Ex-Date	Aug 14, 2026
Dividend Gr. 3/5Y	8.77% -7.68%
Payout	46.93%
Employees	66841
IPO	Mar 28, 1980

P/E	15.94
Forward P/E	10.03
PEG	2.38
P/S	2.27
P/B	4.37
P/C	24.58
P/FCF	11.62
EV/EBITDA	8.56
EV/Sales	2.71
Quick Ratio	0.52
Current Ratio	0.82
Debt/Eq	1.03
LT Debt/Eq	0.79
Option/Short	Yes / Yes

EPS (ttm)	3.17
EPS next Y	5.04
EPS next Q	1.33
EPS this Y	1.59%
EPS next Y	5.59%
EPS next 5Y	4.21%
EPS past 3/5Y	-25.93% 0.08%
Sales past 3/5Y	6.03% -0.31%
EPS Y/Y TTM	48.32%
Sales Y/Y TTM	8.82%
EPS Q/Q	-69.33%
Sales Q/Q	5.87%
Earnings	Oct 28 BMO
EPS/Sales Surpr.	8.28% 1.42%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	17.41%
Inst Trans	-2.06%
ROA	7.95%
ROE	29.69%
ROIC	15.47%
Gross Margin	73.29%
Oper. Margin	25.00%
Profit Margin	14.56%
SMA20	4.72%
SMA50	2.06%
SMA200	-3.38%
Trades

Shs Outstand	2.02B
Shs Float	2.00B
Short Float	0.74%
Short Ratio	3.55
Short Interest	14.80M
52W High	61.69 -18.01%
52W Low	42.85 18.07%
Volatility	1.78% 1.70%
ATR (14)	1.04
RSI (14)	58.67
Beta	0.30
Rel Volume	0.72
Avg Volume	4.17M
Volume	2,208,803

Perf Week	2.17%
Perf Month	1.88%
Perf Quarter	-2.68%
Perf Half Y	-7.08%
Perf YTD	3.15%
Perf Year	11.08%
Perf 3Y	41.30%
Perf 5Y	24.94%
Perf 10Y	20.81%
Recom	2.22
Target Price	56.34
Prev Close	51.21
Price	50.58
Change %	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-26	Initiated	Wolfe Research	Outperform	$70
Sep-15-26	Upgrade	Berenberg	Hold → Buy
Sep-09-26	Initiated	RBC Capital Mkts	Sector Perform
Jul-24-26	Initiated	Citigroup	Neutral
Jul-06-26	Upgrade	HSBC Securities	Reduce → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Jan-06-26	Downgrade	Barclays	Equal Weight → Underweight
Nov-25-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-03-25	Downgrade	Berenberg	Buy → Hold
Apr-15-25	Initiated	Exane BNP Paribas	Neutral	$35.25
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Nov-15-24	Downgrade	Deutsche Bank	Buy → Hold
Nov-12-24	Downgrade	Jefferies	Buy → Hold	$53 → $39.50
Oct-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-08-24	Downgrade	UBS	Buy → Neutral
May-30-24	Initiated	Goldman	Neutral	$47
Mar-04-24	Upgrade	Guggenheim	Neutral → Buy
Feb-13-24	Upgrade	Citigroup	Neutral → Buy
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$44
Jan-16-24	Resumed	UBS	Buy

Show Previous Ratings

Oct-21-26 08:30AM	GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says (Proactive)
Oct-20-26 07:58PM	Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) (Business Wire)
Oct-19-26 06:23AM	Jefferies backs GSK with 2,500p target after positive lung cancer drug results (Proactive)
02:19AM	GSK lung cancer drug shows 61% response rate in early global trial (Proactive)
01:59AM	MARKETS LIVE: London stocks extend losses (Proactive)
10:24AM	Loading…
Oct-13-26 10:24AM	GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength (Proactive)
Oct-10-26 09:19AM	Flu season is already here. Here's what to know about this year's flu shots. (MarketWatch)
Oct-08-26 07:38AM	Viola Davis partners with GSK to educate adults 50 and older about their shingles risk (PR Newswire)
Sep-29-26 07:30AM	GSK retains buy rating at Jefferies as B7H3 cancer programme seen as underappreciated (Proactive)
Sep-15-26 10:51AM	Is the shingles vaccine the secret to living longer and delaying dementia? Here's what the science says. (MarketWatch)
03:12AM	GSK splashes up to $750m on experimental cancer therapy (Proactive)
Sep-04-26 06:10AM	GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says (Proactive)
Sep-03-26 05:30AM	Panmure and Cavendish reiterate buy on Hutchmed after GSK deal (Proactive)
Aug-20-26 09:00AM	GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth (Proactive)
Aug-10-26 02:11PM	Trump Plans to Sign Order on Splitting Up Combined Measles Shot (Bloomberg)
01:30AM	Loading…
Aug-04-26 01:30AM	More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not (Barrons.com)
Jul-29-26 09:03PM	GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ... (GuruFocus.com)
Jul-28-26 03:51PM	GSK Stock Rises as $2.52 Billion Savings Plan Funds Pipeline (GuruFocus.com)
10:03AM	GSK plots £400m Cambridge research hub in push for cancer breakthrough (The Telegraph)
08:10AM	GSK is slashing costs by $2.5 billion to fast-track its drug pipeline (Quartz)
07:31AM	GSK hits three-month high as vaccines help earnings top forecasts (Proactive)
07:25AM	Glaxo: Q2 Earnings Snapshot (Associated Press)
Jul-27-26 09:17AM	Earnings To Watch: GSK PLC (LSE:GSK) Reports Q2 2026 Result (GuruFocus.com)
Jul-22-26 01:58PM	Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer (PR Newswire)
Jul-21-26 08:35AM	Biotech IPO Gains Crush AI Listings With Standout 55% Return (Bloomberg)
Jul-20-26 12:44PM	GSK Drops Chronic Cough Drug as Shares Fall 4.5% (GuruFocus.com)
Jul-17-26 10:30AM	Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower (Proactive)
Jul-13-26 09:25AM	UBS keeps GSK at 'neutral' with focus on chief executive's strategy update (Proactive)
Jun-17-26 04:21PM	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) (Business Wire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
09:42AM	Loading…
Jun-10-26 09:42AM	Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls (The Fly)
08:21AM	GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts (Proactive)
Jun-09-26 04:03PM	GSK Bets Big on Cancer With Nuvalent Deal (GuruFocus.com)
10:10AM	GSK Buys Nuvalent for $10.6 Billion in Major Cancer Push (Bloomberg)
09:20AM	GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium (GuruFocus.com)
08:16AM	Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal (Barrons.com)
06:06AM	NUVL Stock Surges 39% Premarket Why Is GSK Buying This Boston-Based Oncology Company? (Stocktwits)
05:56AM	Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move. (Barrons.com)
03:37AM	GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down (MarketWatch)
02:25AM	GSK falls as £8bn takeover of Nuvalent is largest deal in a decade (Proactive)
02:25AM	GSK falls after agreeing £8bn Nuvalent takeover to bolster oncology pipeline (Proactive)
02:25AM	GSK agrees £8bn Nuvalent takeover to bolster oncology pipeline (Proactive)
Jun-04-26 07:57AM	US bank sees GSK oncology pipeline as major value driver after New York conference (Proactive)
Jun-03-26 07:54AM	UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags (Proactive)
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
May-29-26 09:30AM	GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading (Proactive)
May-28-26 06:22PM	GSK Drug Shows 19%-20% Hepatitis B Cure Rate In Late-Stage Trials (GuruFocus.com)
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire)
May-12-26 06:23AM	GSK and SBP Group team up to advance bepirovirsen launch in China (Pharmaceutical Business Review)
Apr-30-26 09:32AM	JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited (Proactive)
03:05AM	GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion (GuruFocus.com)
Apr-29-26 06:09AM	American industry is winning: White House touts factory boom how investors can ride the reshoring wave (Moneywise) -5.64%
02:42AM	Glaxo: Q1 Earnings Snapshot (Associated Press)
02:35AM	GSK Q1 Core Profit Rises; Affirms 2026 Guidance (RTT News)
02:19AM	GSK reaffirms 2026 guidance after strong first-quarter performance (Proactive)
Apr-27-26 02:58AM	GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio (Proactive)
Apr-13-26 12:48PM	GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% (GuruFocus.com)
Mar-30-26 10:44AM	Pharma Stocks Pfizer, GSK Offer Defensive Plays in an Uncertain Market: Charts (Barrons.com)
Mar-25-26 10:15AM	Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud (Proactive)
Mar-13-26 11:44AM	GSKs RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 1849 Years at Increased Risk (Business Wire)
Mar-11-26 06:32AM	FDA approves GSK's Wellcovorin for cerebral folate deficiency (Pharmaceutical Business Review)
Mar-10-26 01:59PM	FDA Expands Use Of Generic Drug To Treat Autism-Linked Genetic Disorder (Benzinga)
11:38AM	GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma (Zacks)
11:31AM	JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer (Zacks)
Mar-09-26 05:05PM	Top Stock Reports for Visa, Chevron & Toyota Motor (Zacks)
04:12AM	GSK sells rights to rare liver disease drug for up to $690m (Proactive)
03:39AM	GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million (The Wall Street Journal)
Mar-08-26 06:58PM	Is It Too Late to Buy GSK After a 46% Share Price Jump? (24/7 Wall St.)
04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
Mar-02-26 07:49AM	MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
Feb-26-26 09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
Feb-25-26 07:22AM	GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play (Benzinga)
02:27AM	GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments (Proactive)
Feb-24-26 11:43AM	GSK Strikes $1 Billion China RNA Deal (GuruFocus.com)
11:31AM	SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus (Zacks)
02:11AM	GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study (Insider Monkey)
Feb-23-26 01:13PM	Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract (Business Wire)
Feb-19-26 11:31AM	Europe Clears GSK's New Twice-Yearly Asthma Treatment (Benzinga)
10:30AM	Moderna Stock Jumps After FDA Reverses Course on Flu Shot (Zacks)
07:56AM	Merck Discloses Positive Data For Respiratory Syncytial Virus Antibody Treatment, Seeks FDA Nod For Broader Child Use (Benzinga)
Feb-18-26 08:00AM	GSKs AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows (Business Wire)
Feb-17-26 06:31AM	Europe Clears GSK's New Twice-Yearly Asthma Treatment (Benzinga)
Feb-15-26 09:10AM	GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17% (Insider Monkey)
Feb-13-26 10:59AM	Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms (Benzinga)
09:36AM	Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026? (Zacks)
Feb-11-26 10:15AM	GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales (Zacks)
Feb-09-26 07:15AM	Citi lifts GSK target price but keeps neutral stance after rally (Proactive)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
05:15AM	ShoreCap says GSK has cracked it and the £40bn prize is now in sight (Proactive)
Feb-05-26 09:15AM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? (Zacks)
02:04AM	Analyst Report: GSK plc (Morningstar Research)
Feb-04-26 09:00PM	Analyst Report: GSK plc (Morningstar Research) +7.29%
04:05PM	GSK Is Eyeing $55 Billion In Sales And It Has Nothing To Do With Obesity (Investor's Business Daily)
01:52PM	GSK Shares Jump 5.2% as New CEO Signals Faster R&D, Deal Push (GuruFocus.com)
01:50PM	GSK Beats Estimates, Sticks With Long-Term Outlook (GuruFocus.com)
12:01PM	GSK PLC (GSK) Q4 2025 Earnings Call Highlights: Strong Financial Performance and Strategic ... (GuruFocus.com)
10:30AM	GSK beat the numbers, but the real story was the guidance (Proactive)
08:31AM	GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martinez Maria E	Officer	Aug 20 '26	Proposed Sale	52.08	44,397	2,312,107		Aug 20 11:19 AM

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations and Total Research and Development. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in London, the United Kingdom.

CFO & Executive DirectorMs. Julie Belita Brown A.C.A.

M.P.H.Dr. Jesse L. Goodman M.D.

CEO & DirectorMr. Luke Victor Miels

Chief Digital & Technology OfficerMs. Shobie Ramakrishnan

Chief Scientific Officer and Head of R&DMr. Tony Wood

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GSK Plc ADR

Upgrade your Finviz experience